{"result": "(\"entity\"<|>OBESITY SOCIETY<|>ORGANIZATION<|>The Obesity Society is a professional organization focused on the study and treatment of obesity, providing guidelines and research on obesity management.)\n##\n(\"entity\"<|>MIDDLETON KM<|>PERSON<|>Middleton KM is a researcher who has contributed to studies on the long-term maintenance of weight loss.)\n##\n(\"entity\"<|>PATRIDAR SM<|>PERSON<|>Patidar SM is a researcher involved in the systematic review and meta-analysis of extended care for weight loss maintenance.)\n##\n(\"entity\"<|>PERRI MG<|>PERSON<|>Perri MG is a researcher who has worked on obesity treatment and weight loss maintenance strategies.)\n##\n(\"entity\"<|>KRENTZ AJ<|>PERSON<|>Krentz AJ is a researcher focusing on pharmacological treatments for obesity and their side effects.)\n##\n(\"entity\"<|>FUJIOKA K<|>PERSON<|>Fujioka K is a researcher who has contributed to the understanding of obesity pharmacology and treatment.)\n##\n(\"entity\"<|>HOMPESCH M<|>PERSON<|>Hompesch M is a researcher involved in the evolution of pharmacological treatments for obesity.)\n##\n(\"entity\"<|>CABRERIZO-GARCÍA L<|>PERSON<|>Cabrerizo-García L is a researcher who has updated the pharmacology of obesity treatments.)\n##\n(\"entity\"<|>RUBIO-HERRERA MA<|>PERSON<|>Rubio-Herrera MA is a researcher contributing to the pharmacological management of obesity.)\n##\n(\"entity\"<|>APOVIAN CM<|>PERSON<|>Apovian CM is a researcher who has authored clinical practice guidelines for the pharmacological management of obesity.)\n##\n(\"entity\"<|>ARONNE LJ<|>PERSON<|>Aronne LJ is a researcher involved in obesity management and treatment guidelines.)\n##\n(\"entity\"<|>BESSEN DH<|>PERSON<|>Bessen DH is a researcher who has contributed to obesity pharmacological management studies.)\n##\n(\"entity\"<|>MCDONNELL ME<|>PERSON<|>McDonnell ME is a researcher involved in obesity treatment guidelines.)\n##\n(\"entity\"<|>MURAD MH<|>PERSON<|>Murad MH is a researcher who has contributed to the pharmacological management of obesity.)\n##\n(\"entity\"<|>PAGOTTO U<|>PERSON<|>Pagotto U is a researcher involved in obesity management and treatment guidelines.)\n##\n(\"entity\"<|>BLOSSOM CLINICAL TRIAL GROUP<|>ORGANIZATION<|>The BLOSSOM Clinical Trial Group is a research group that conducted a trial on lorcaserin for weight loss in obese and overweight adults.)\n##\n(\"entity\"<|>FIDLER MC<|>PERSON<|>Fidler MC is a researcher involved in the BLOSSOM trial for weight loss.)\n##\n(\"entity\"<|>SANCHEZ M<|>PERSON<|>Sanchez M is a researcher who participated in the BLOSSOM trial for weight loss.)\n##\n(\"entity\"<|>RAETHER B<|>PERSON<|>Raether B is a researcher involved in the BLOSSOM trial for weight loss.)\n##\n(\"entity\"<|>WEISSMAN NJ<|>PERSON<|>Weissman NJ is a researcher who contributed to the BLOSSOM trial for weight loss.)\n##\n(\"entity\"<|>SMITH SR<|>PERSON<|>Smith SR is a researcher involved in the BLOSSOM trial for weight loss.)\n##\n(\"entity\"<|>SHANAHAN WR<|>PERSON<|>Shanahan WR is a researcher who participated in the BLOSSOM trial for weight loss.)\n##\n(\"entity\"<|>ANDERSON CM<|>PERSON<|>Anderson CM is a researcher involved in the BLOSSOM trial for weight loss.)\n##\n(\"entity\"<|>O'NEIL PM<|>PERSON<|>O'Neil PM is a researcher who contributed to the BLOOM-DM study on weight loss in type 2 diabetes.)\n##\n(\"entity\"<|>ZHANG J<|>PERSON<|>Zhang J is a researcher involved in the BLOOM-DM study for weight loss.)\n##\n(\"entity\"<|>KHERAR<|>PERSON<|>Khera R is a researcher who has conducted systematic reviews on pharmacological treatments for obesity.)\n##\n(\"entity\"<|>GARVEY WT<|>PERSON<|>Garvey WT is a researcher who has contributed to clinical practice guidelines for obesity management.)\n##\n(\"entity\"<|>MECHANICK JI<|>PERSON<|>Mechanick JI is a researcher involved in obesity management guidelines.)\n##\n(\"entity\"<|>BRETT EM<|>PERSON<|>Brett EM is a researcher who has contributed to obesity management guidelines.)\n##\n(\"entity\"<|>GARBER AJ<|>PERSON<|>Garber AJ is a researcher involved in obesity management guidelines.)\n##\n(\"entity\"<|>HURLEY DL<|>PERSON<|>Hurley DL is a researcher who has contributed to obesity management guidelines.)\n##\n(\"entity\"<|>JASTREBOFF AM<|>PERSON<|>Jastreboff AM is a researcher involved in obesity management guidelines.)\n##\n(\"entity\"<|>ALLISON DB<|>PERSON<|>Allison DB is a researcher who has conducted studies on pharmacotherapy for obesity.)\n##\n(\"entity\"<|>GADDE KM<|>PERSON<|>Gadde KM is a researcher involved in obesity pharmacotherapy studies.)\n##\n(\"entity\"<|>RYAN DH<|>PERSON<|>Ryan DH is a researcher who has contributed to obesity pharmacotherapy studies.)\n##\n(\"entity\"<|>PETRSON CA<|>PERSON<|>Peterson CA is a researcher involved in obesity pharmacotherapy studies.)\n##\n(\"entity\"<|>SCHWIERS ML<|>PERSON<|>Schwiers ML is a researcher who has contributed to obesity pharmacotherapy studies.)\n##\n(\"entity\"<|>NAJARIAN T<|>PERSON<|>Najarian T is a researcher involved in obesity pharmacotherapy studies.)\n##\n(\"entity\"<|>TROUPIN B<|>PERSON<|>Troupin B is a researcher who has contributed to obesity pharmacotherapy studies.)\n##\n(\"entity\"<|>DAY WW<|>PERSON<|>Day WW is a researcher involved in obesity pharmacotherapy studies.)\n##\n(\"entity\"<|>GADDE KM<|>PERSON<|>Gadde KM is a researcher who has contributed to studies on controlled-release phentermine/topiramate for obesity treatment.)\n##\n(\"entity\"<|>RUCKER D<|>PERSON<|>Rucker D is a researcher who has conducted meta-analyses on long-term pharmacotherapy for obesity.)\n##\n(\"entity\"<|>PADWAL R<|>PERSON<|>Padwal R is a researcher involved in meta-analyses on obesity pharmacotherapy.)\n##\n(\"entity\"<|>LI SK<|>PERSON<|>Li SK is a researcher who has contributed to meta-analyses on obesity pharmacotherapy.)\n##\n(\"entity\"<|>CURIONI C<|>PERSON<|>Curioni C is a researcher involved in meta-analyses on obesity pharmacotherapy.)\n##\n(\"entity\"<|>LAU DCW<|>PERSON<|>Lau DCW is a researcher who has contributed to meta-analyses on obesity pharmacotherapy.)\n##\n(\"entity\"<|>TORGERSON JS<|>PERSON<|>Torgerson JS is a researcher involved in the XENDOS study on obesity prevention.)\n##\n(\"entity\"<|>HAUPTMAN J<|>PERSON<|>Hauptman J is a researcher who has contributed to the XENDOS study on obesity prevention.)\n##\n(\"entity\"<|>BOLDRIN MN<|>PERSON<|>Boldrin MN is a researcher involved in the XENDOS study on obesity prevention.)\n##\n(\"entity\"<|>SJÖSTRÖM L<|>PERSON<|>Sjöström L is a researcher who has contributed to the XENDOS study on obesity prevention.)\n##\n(\"entity\"<|>ANDERSON JW<|>PERSON<|>Anderson JW is a researcher involved in studies on bupropion SR for weight loss.)\n##\n(\"entity\"<|>GREENWAY FL<|>PERSON<|>Greenway FL is a researcher who has contributed to studies on naltrexone plus bupropion for weight loss.)\n##\n(\"entity\"<|>PLodkowski RA<|>PERSON<|>Plodkowski RA is a researcher involved in studies on naltrexone plus bupropion for weight loss.)\n##\n(\"entity\"<|>MUDALIAR S<|>PERSON<|>Mudaliar S is a researcher who has contributed to studies on naltrexone plus bupropion for weight loss.)\n##\n(\"entity\"<|>GUTTADAIRA M<|>PERSON<|>Guttadaira M is a researcher involved in studies on naltrexone plus bupropion for weight loss.)\n##\n(\"entity\"<|>ERIKSON J<|>PERSON<|>Erikson J is a researcher who has contributed to studies on naltrexone plus bupropion for weight loss.)\n##\n(\"entity\"<|>KIM DD<|>PERSON<|>Kim DD is a researcher involved in studies on naltrexone plus bupropion for weight loss.)\n##\n(\"entity\"<|>DUNAYEVICH E<|>PERSON<|>Dunayevich E is a researcher who has contributed to studies on naltrexone plus bupropion for weight loss.)\n##\n(\"entity\"<|>APOVIAN CM<|>PERSON<|>Apovian CM is a researcher involved in the COR-II study on naltrexone SR/bupropion SR for weight loss.)\n##\n(\"relationship\"<|>MIDDLETON KM<|>OBESITY SOCIETY<|>Middleton KM is a researcher contributing to the Obesity Society's studies on weight loss maintenance<|>7)\n##\n(\"relationship\"<|>PATRIDAR SM<|>OBESITY SOCIETY<|>Patidar SM is a researcher contributing to the Obesity Society's studies on weight loss maintenance<|>7)\n##\n(\"relationship\"<|>PERRI MG<|>OBESITY SOCIETY<|>Perri MG is a researcher contributing to the Obesity Society's studies on weight loss maintenance<|>7)\n##\n(\"relationship\"<|>KRENTZ AJ<|>OBESITY SOCIETY<|>Krentz AJ is a researcher contributing to the Obesity Society's studies on pharmacological treatments for obesity<|>7)\n##\n(\"relationship\"<|>FUJIOKA K<|>OBESITY SOCIETY<|>Fujioka K is a researcher contributing to the Obesity Society's studies on pharmacological treatments for obesity<|>7)\n##\n(\"relationship\"<|>HOMPESCH M<|>OBESITY SOCIETY<|>Hompesch M is a researcher contributing to the Obesity Society's studies on pharmacological treatments for obesity<|>7)\n##\n(\"relationship\"<|>CABRERIZO-GARCÍA L<|>OBESITY SOCIETY<|>Cabrerizo-García L is a researcher contributing to the Obesity Society's studies on pharmacological treatments for obesity<|>7)\n##\n(\"relationship\"<|>RUBIO-HERRERA MA<|>OBESITY SOCIETY<|>Rubio-Herrera MA is a researcher contributing to the Obesity Society's studies on pharmacological treatments for obesity<|>7)\n##\n(\"relationship\"<|>APOVIAN CM<|>OBESITY SOCIETY<|>Apovian CM is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>ARONNE LJ<|>OBESITY SOCIETY<|>Aronne LJ is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>BESSEN DH<|>OBESITY SOCIETY<|>Bessen DH is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>MCDONNELL ME<|>OBESITY SOCIETY<|>McDonnell ME is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>MURAD MH<|>OBESITY SOCIETY<|>Murad MH is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>PAGOTTO U<|>OBESITY SOCIETY<|>Pagotto U is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>FIDLER MC<|>BLOSSOM CLINICAL TRIAL GROUP<|>Fidler MC is a researcher involved in the BLOSSOM trial for weight loss<|>8)\n##\n(\"relationship\"<|>SANCHEZ M<|>BLOSSOM CLINICAL TRIAL GROUP<|>Sanchez M is a researcher involved in the BLOSSOM trial for weight loss<|>8)\n##\n(\"relationship\"<|>RAETHER B<|>BLOSSOM CLINICAL TRIAL GROUP<|>Raether B is a researcher involved in the BLOSSOM trial for weight loss<|>8)\n##\n(\"relationship\"<|>WEISSMAN NJ<|>BLOSSOM CLINICAL TRIAL GROUP<|>Weissman NJ is a researcher involved in the BLOSSOM trial for weight loss<|>8)\n##\n(\"relationship\"<|>SMITH SR<|>BLOSSOM CLINICAL TRIAL GROUP<|>Smith SR is a researcher involved in the BLOSSOM trial for weight loss<|>8)\n##\n(\"relationship\"<|>SHANAHAN WR<|>BLOSSOM CLINICAL TRIAL GROUP<|>Shanahan WR is a researcher involved in the BLOSSOM trial for weight loss<|>8)\n##\n(\"relationship\"<|>ANDERSON CM<|>BLOSSOM CLINICAL TRIAL GROUP<|>Anderson CM is a researcher involved in the BLOSSOM trial for weight loss<|>8)\n##\n(\"relationship\"<|>O'NEIL PM<|>BLOOM-DM STUDY<|>O'Neil PM is a researcher involved in the BLOOM-DM study for weight loss in type 2 diabetes<|>8)\n##\n(\"relationship\"<|>ZHANG J<|>BLOOM-DM STUDY<|>Zhang J is a researcher involved in the BLOOM-DM study for weight loss in type 2 diabetes<|>8)\n##\n(\"relationship\"<|>KHERAR<|>OBESITY SOCIETY<|>Khera R is a researcher contributing to the Obesity Society's systematic reviews on pharmacological treatments for obesity<|>7)\n##\n(\"relationship\"<|>GARVEY WT<|>OBESITY SOCIETY<|>Garvey WT is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>MECHANICK JI<|>OBESITY SOCIETY<|>Mechanick JI is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>BRETT EM<|>OBESITY SOCIETY<|>Brett EM is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>GARBER AJ<|>OBESITY SOCIETY<|>Garber AJ is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>HURLEY DL<|>OBESITY SOCIETY<|>Hurley DL is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>JASTREBOFF AM<|>OBESITY SOCIETY<|>Jastreboff AM is a researcher contributing to the Obesity Society's clinical practice guidelines for obesity management<|>7)\n##\n(\"relationship\"<|>ALLISON DB<|>OBESITY SOCIETY<|>Allison DB is a researcher contributing to the Obesity Society's studies on pharmacotherapy for obesity<|>7)\n##\n(\"relationship\"<|>GADDE KM<|>OBESITY SOCIETY<|>Gadde KM is a researcher contributing to the Obesity Society's studies on pharmacotherapy for obesity<|>7)\n##\n(\"relationship\"<|>RYAN DH<|>OBESITY SOCIETY<|>Ryan DH is a researcher contributing to the Obesity Society's studies on pharmacotherapy for obesity<|>7)\n##\n(\"relationship\"<|>PETRSON CA<|>OBESITY SOCIETY<|>Peterson CA is a researcher contributing to the Obesity Society's studies on pharmacotherapy for obesity<|>7)\n##\n(\"relationship\"<|>SCHWIERS ML<|>OBESITY SOCIETY<|>Schwiers ML is a researcher contributing to the Obesity Society's studies on pharmacotherapy for obesity<|>7)\n##\n(\"relationship\"<|>NAJARIAN T<|>OBESITY SOCIETY<|>Najarian T is a researcher contributing to the Obesity Society's studies on pharmacotherapy for obesity<|>7)\n##\n(\"relationship\"<|>TROUPIN B<|>OBESITY SOCIETY<|>Troupin B is a researcher contributing to the Obesity Society's studies on pharmacotherapy for obesity<|>7)\n##\n(\"relationship\"<|>DAY WW<|>OBESITY SOCIETY<|>Day WW is a researcher contributing to the Obesity Society's studies on pharmacotherapy for obesity<|>7)\n##\n(\"relationship\"<|>GADDE KM<|>BLOSSOM CLINICAL TRIAL GROUP<|>Gadde KM is a researcher involved in the BLOSSOM trial for weight loss<|>8)\n##\n(\"relationship\"<|>RUCKER D<|>OBESITY SOCIETY<|>Rucker D is a researcher", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: The Obesity Society. J Am Coll Cardiol. 2014; 63(25 Pt B): 2985-3023.\n\n2. Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obesity Rev. 2012; 13: 509-17.\n\n3. Krentz AJ, Fujioka K,Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metabol. 2016; 18: 558-570.\n\n4. Cabrerizo-García L, Ramos-Leví A, Moreno-Lopera C, Rubio-Herrera MA. Update on pharmacology of obesity: Benefits and risks. Nutr Hosp 2013; 28 Suppl 5:121-7.\n\n5. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100: 342-62.\n\n6. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96:3067-3077.\n\n7. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363:245-256.\n\n8. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR. Randomized placebo controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012; 20: 1426-1436.\n\n9. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesitywithweight loss and adverse events. A systematic review and meta-analysis. JAMA. 2016; 315: 2424-34.\n\n10. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.Endocr Pract. 2016;22 Suppl 3:1-203.\n\n11. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day\n---\n140      BLOQUE: ALTERACIONES DE LA ENERGÍA\n\nWW. Controlled-release phentermine/ topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012; 20:330-42.\n\n12. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebocontrolled, phase 3 trial. Lancet. 2011; 377:1341-52.\n\n13. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012; 95:297-308.\n\n14. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007; 335 (7631): 1194-9.\n\n15. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004; 27:155-61.\n\n16. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10: 633-641.\n\n17. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadaira M, Erikson J, Kim DD, Dunayevich E, for the COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376: 595-605.\n\n18. Apovian CM, Aronne L, Rubino D,Still C, Wyatt H, Burns C, et al;COR-II Study Group. A randomized, phase 3 trial ofnaltrexone SR/bupropion SR on weight\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}